▶ 調査レポート

サイトカインの世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Cytokine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。サイトカインの世界市場2021-2026:成長・動向・新型コロナの影響・市場予測 / Cytokine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) / MRC2103C088資料のイメージです。• レポートコード:MRC2103C088
• 出版社/出版日:Mordor Intelligence / 2021年2月25日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥561,000 (USD4,250)▷ お問い合わせ
  Team User¥627,000 (USD4,750)▷ お問い合わせ
  Corporate License¥990,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査資料では、世界のサイトカイン市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、サイトカイン別(腫瘍壊死因子-TNF、インターロイキン-Il、インターフェロン-IFN、表皮成長因子-EGF、その他)分析、治療用途別(癌、喘息・気道炎症、関節炎、その他)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界のサイトカイン市場規模:サイトカイン別(腫瘍壊死因子-TNF、インターロイキン-Il、インターフェロン-IFN、表皮成長因子-EGF、その他)
・世界のサイトカイン市場規模:治療用途別(癌、喘息・気道炎症、関節炎、その他)
・世界のサイトカイン市場規模:地域別
・競争状況
・市場機会/将来の見通し

Cytokines are molecular messengers that allow the cells of the immune system to communicate with one another, to generate a coordinated, robust, but self-limited response to a target antigen. There are two types of cytokines used to treat patients with cancer, namely, interferons (INFs) and interleukins (ILs). A third type, called hematopoietic growth factors, is used to counteract some of the side effects of certain chemotherapy regimens. The growing interest, over the past two decades, in harnessing the immune system to eradicate cancer has been accompanied by heightened efforts to characterize cytokines and exploit their vast signaling networks, to develop cancer treatments. They directly stimulate immune effector cells and stromal cells at the tumor site and enhance tumor cell recognition by cytotoxic effector cells. Numerous animal tumor model studies have demonstrated that cytokines have broad anti-tumor activity, which has been translated into a number of cytokine-based approaches for cancer therapy. Cytokines have proven to be effective in the treatment of cancer and may continue to play a major role in the development of cancer immunotherapy. Cytokines are finding increasing acceptance in cancer therapy over the world.

Key Market Trends

Application in Cancer is Expected to Hold the Largest Share of the Market

The mixture of cytokines that are produced in the cancer microenvironment has an important role in cancer pathogenesis. Cytokines that are released in response to infection, inflammation, and immunity can function to inhibit cancer development and progression. Alternatively, cancer cells can respond to host-derived cytokines that promote growth, attenuate apoptosis, and facilitate invasion and metastasis. To circumvent these impediments, cytokines are have been investigated clinically with new engineered cytokine mutants (superkines), chimeric antibody-cytokine fusion proteins (immunokines), anticancer vaccines, checkpoint inhibitors, and cancer-directed monoclonal antibodies to increase their antibody-dependent cellular cytotoxicity or sustain cellular responses and anticancer efficacy.

Moreover, the demand for this therapy is expected to increase as Cancer Research UK suggests that the population suffering from cancer is expected to increase across the globe in the future. As per the report, if recent trends in incidence of major cancers and population growth are consistent, it is predicted there will be 27.5 million new cancer cases worldwide each year by 2040, as compared to 17 million in 2018. This factor is, hence, expected to help the market growth.

North American Region Holds the Largest Market Share of the Cytokine Market

North America is dominating the cytokine market, due to the rising prevalence of cancer in the region. Numerous animal tumour model studies have demonstrated that cytokines have broad anti-tumour activity, which has been translated into a number of cytokine-based approaches for cancer therapy. As per the American Cancer Society, there were an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States, numbers which are expected to rise in future. Augmenting growth in the R&D of cancer therapy, along with lesser side effects (as compared to chemotherapy), has predisposed cytokine therapy, which is a non-specific immunotherapy. This factor has increased the market share of cytokines among cancer therapies, in the United States.

Competitive Landscape

The cytokine market consists of several major players. The comapanies are implementing certain strategic initiatives, such as a mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. For instance, in October 2017, US FDA approved Stelara (ustekinumab) for the treatment of adolescents with moderate-to-severe plaque psoriasis, which is developed by Janssen Pharmaceutica.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Acceptance in Cancer Therapy
4.2.2 Use of Cytokine as a Potential Biomarker for Neonatal Sepsis
4.2.3 Potential Contribution in Stem Cell Therapy
4.3 Market Restraints
4.3.1 High Costs
4.3.2 Lacks Specificity
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Cytokine Type
5.1.1 Tumor Necrosis Factor-TNF
5.1.2 Interleukins-Il
5.1.3 Interferons-IFN
5.1.4 Epidermal Growth Factor-EGF
5.1.5 Other Cytokine Types
5.2 By Therapeutic Application
5.2.1 Cancer
5.2.2 Asthma and Airway Inflammation
5.2.3 Arthritis
5.2.4 Other Therapeutic Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithkline PLC
6.1.2 Novartis International AG
6.1.3 Amgen
6.1.4 Pfizer Inc.
6.1.5 Sanofi SA
6.1.6 AstraZeneca plc
6.1.7 Biocon Limited
6.1.8 Abbvie Inc
6.1.9 Johnson and Johnson
6.1.10 UCB S.A

7 MARKET OPPORTUNITIES AND FUTURE TRENDS